You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 8, 2025

New Draft Regulatory Framework for Food Product Declaration and Registration in Vietnam

Subscribe to Updates

In response to persistent challenges in food safety management and recent high-profile incidents involving counterfeit supplemented foods, infant formula, and health supplements, the Ministry of Health of Vietnam is initiating comprehensive regulatory reforms. These reforms include proposed amendments to the Law on Food Safety and its implementing Decree No. 15/2018/ND-CP (Decree 15), introducing significant changes to the registration procedures for food products, especially supplemented food products and health supplements.

While awaiting public consultation and approval of the amended Law on Food Safety, the Ministry of Health is developing an interim mechanism, which includes a draft decree to replace Decree 15 and a draft resolution to address urgent issues until the amended law becomes effective, expected in July 2026.

To align with the new Law on Quality of Products and Goods, the draft resolution stipulates that the declaration and registration of food products will follow the following procedures:

  • Declaration of applied standards for food products, which is currently known as the “self-declaration” procedure, applies to processed packaged foods, food additives, food processing aids, containers or utensils that come into direct contact with food, packaging materials in direct contact with food, and micronutrients.
  • Granting of circulation numbers, which is the current “registration of product declaration” procedure, applies to specific categories of food including health supplements, medical nutrition foods, special dietary foods, nutritional products for children up to 36 months, and, especially, supplemented foods, which are currently subject to self-declaration but will be shifted to this registration procedure.

In addition, the following new procedure is introduced in the draft decree:

  • Registration of declaration of conformity, which applies to the same product category as in “declaration of applied standards” above, but is for products that are already subject to technical regulations covering both safety indicators and quality indicators.

Changes to the Food Product Declaration and Registration Procedures

Details of the procedures for declaration of applied standards and granting of circulation numbers are stipulated in the draft resolution, while details of the procedure for registration of declaration of conformity are stipulated in the draft decree. These procedures will see some key changes compared to the current regulations, as highlighted below:

  • Letter of authorization: A letter of authorization (LOA) from the manufacturer or product owner to the entity conducting the declaration of applied standard or registration is a new requirement applicable to both procedures. Information that must be included in the LOA is detailed in the draft resolution.
  • Quality criteria: It is newly required to test quality criteria in a Certificate of Analysis (COA), in addition to safety criteria, for both procedures. The COA will need to follow the format set out in the draft resolution.
  • Declaration of conformity with internal standards: In addition to the declaration of compliance with food safety requirements, both product declaration and registration procedures have a new requirement that the declaring or registering entity must confirm that the product complies with its internal standards. This conformity is substantiated by submitting the in-house specification along with a dossier detailing the development of the specification.
  • Timeline for declaration of applied standards: The draft resolution introduces a defined principal evaluation timeline of 21 days from the date of submission—an element not specified under current regulations. It also clarifies that entities may begin manufacturing and trading declared products once the declaration, including the entity name and product name, is published on the authority’s official website.
  • Required documents: The required documents applicable to products subject to the registration of product declaration procedure are much more stringent than in current practice. The registration dossier will cover two parts: (i) administrative and (ii) technical. More technical documents will be required for the technical part, such as a manufacturer’s certificate (GMP, HACCP, etc.), report on product research and development process, documentation on quality and safety standards, documentation of manufacturing process, long-term stability report, and other technical explanation (if necessary).
  • Timeline for registration of product declaration: The estimated principal approval timeline is specifically set as 90 days from the date of submission. Compared to the current regulation, the timeline for submitting a supplemental dossier will be reduced from 90 working days to 60 working days from the date of receiving an official notice of deficiency. Notably, instead of an unlimited number of revisions, the draft resolution only permits a one-time revision.
  • Exclusion of certain products from the registration of product declaration procedure: Certain food additives—including blended food additives with new functions, those not on the Ministry of Health’s permitted list, or those used for incorrect purposes—are no longer subject to the registration of product declaration procedure under the draft resolution. Neither the draft resolution nor the draft decree specify how these products should be registered, suggesting that future regulations on food additive management may address this gap.

Suspension of Product Declaration Registration

The draft resolution introduces a new provision allowing competent authorities to temporarily suspend the receipt and processing of product declaration dossiers from entities who have violated food safety regulations. Processing will resume once the violations are fully remedied and a compliance report is submitted.

Transitional Provision

Under the draft decree, for food products that are registered or self-declared before the effective date of the decree, product owners must complete the procedures for re-registering or re-declaring product standards in accordance with the draft resolution (after it is enacted), within the following timeframes:

  • 18 months from the effective date of the decree for products that already have a Certificate of Receipt for Product Declaration.
  • 6 months from the effective date of the decree for products that are self-declared.

After these deadlines, any previous product declaration documents or certificates will no longer be valid for production or importation. However, products with a certificate that were produced within 18 months of the decree’s effective date and products that were self-declared and produced within 6 months of the decree’s effective date may continue to be circulated until their expiration date, and the product owner remains fully responsible for those products.

The draft decree does not specify a transitional period for the supplemented food products that will be shifted from the self-declaration procedure to the registration of product declaration procedure.

The draft resolution and draft decree will be discussed and approved under the fast-track procedure. However, no expected effective date has been provided. It remains possible that further revisions to the draft decree may be introduced.

Impact for Businesses and Next Steps

Businesses will be required to prepare additional documentation for declaration and registration processes to comply with the new regulations once they are enacted. Stricter documentation will be required for products subject to registration of declaration procedure, especially for supplemented foods, which are shifted from self-declaration procedure to registration of product declaration procedure.

Businesses should review their product portfolios to determine applicable registration pathways, develop plans to update the declaration and registration dossiers, and monitor for further amendment, official issuance, and implementation guidance.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

January 8, 2026
Thailand’s approach to cannabis regulation has moved quickly from broad access to a medical, prescription‑only system. The latest government regulation classifies the cannabis flower as a controlled herb under the Thai Traditional Medicine Wisdom Act. The latest rules ban advertising and recreational sales, allow sales only to patients with prescriptions (up to 30 days), and require flowers to come from GACP‑certified (Good Agricultural and Collection Practices) farms. More importantly, cannabis dispensaries can only sell to patients presenting valid prescriptions issued by one of seven professions—medical doctors, Thai traditional practitioners, applied Thai traditional practitioners, traditional Chinese medicine practitioners, pharmacists, dentists, and folk healers—consistent with approved clinical indications. Noncompliance risks license suspension or revocation, and criminal penalties of up to one year’s imprisonment or a THB 20,000 fine. The dispensary‑only model that proliferated in Thailand in recent years is expected to end soon, as the rules will push all cannabis dispensaries into medical settings or retail pharmacies. Dispensaries must convert into medical establishments—clinics, pharmacies, or traditional pharmacies—complete with on‑site licensed practitioners as well as budtenders; strong controls for storage, hygiene, odor, and smoke; and facilities for record-keeping. All flowers dispensed or exported must come from GACP‑certified farms. If the government ends dispensaries outright and forces a conversion to clinics or pharmacies, compensation will not be automatic at the outset. As a result, business operators should plan for compliance and repurposing under the Medical Facilities Act, Modern Drug Act, and Herbal Product Act, which regulate medical clinics, modern pharmacies, and traditional medicine pharmacies, respectively. The table below summarizes the required licenses for clinics, pharmacies, and traditional medicine pharmacies selling cannabis flowers in Thailand. Aside from the specific listed licenses, all three types of establishments must also obtain a license to sell a controlled herb (cannabis flowers) from the Department of Thai Traditional
Read More
January 6, 2026
On December 30, 2025, Thailand’s Electronic Transactions Development Agency (ETDA) notified digital marketplace operators of a consolidated list of “high‑risk products” that are subject to strict monitoring on digital platforms. The list was jointly prepared by the Thai Industrial Standards Institute (TISI) and the Food and Drug Administration (FDA) to guide platform compliance in the initial phase of implementation of the Electronic Transaction Committee’s Notification on Other Measures for Marketplace for Goods with Specific Characteristics under Section 18(2) of the 2022 Royal Decree on Digital Platform Businesses Requiring Notification B.E.2568 (2025). The notice is addressed to operators of digital platform services that function as product marketplaces with specific characteristics laid out in the notification. The ETDA states that the TISI and the FDA are closely monitoring the high‑risk product categories on digital platforms, and the published list serves as the baseline reference for platform screening during the initial phase of the notification’s implementation. High‑Risk Product List The list aggregates categories of products that are illegal to sell online or are otherwise tightly regulated under Thai law, with an emphasis on health-related products, controlled substances, medical devices, and a wide range of industrial products that require certification or compliance with specified Thai Industrial Standards, as detailed below. Prohibited and tightly controlled health products. This includes all categories of modern medicines subject to control other than general household remedies; all categories of controlled herbal products except for over-the-counter herbal products; narcotics; psychotropic substances; and medical devices requiring use in medical facilities or a physician’s prescription. Selected industrial products requiring heightened controls. The list highlights dozens of TISI-regulated items commonly sold online. Examples include pacifiers, rice cookers, electrical wire, food wrap film, crayons, washing machines and dryers, air conditioners, electric cookers and air fryers, water heaters, microwave ovens, LED luminaires, hair dryers
Read More
January 5, 2026
On December 31, 2025, Vietnam’s Ministry of Health (MOH) issued Circular No. 57/2025/TT-BYT providing guidance on the classification of medical devices according to technical standards and quality requirements (Circular 57), applicable to procurement activities for medical devices in Vietnam. According to the MOH, the purpose of the classification is to establish a principle-based legal framework and regulations that enable purchasers to easily identify groups of medical devices aligned with their professional requirements and financial capacity. Some of the key stipulations of Circular 57 are outlined below. Basis for Determining Technical Standards and Quality Under Circular 57, the technical standards of medical devices are determined in accordance with Vietnamese laws on standards and technical regulations, through the following means: Certification of conformity with standards in accordance with Vietnamese laws on standards and technical regulations; Results of conformity assessment conducted by an internationally recognized conformity assessment organization or a legally established domestic or foreign conformity assessment organization operating in Vietnam; and Documentation evidencing compliance provided by the medical device owner. The quality of medical devices is determined based on whether the device has been approved for circulation by the relevant marketing authority of one or more jurisdictions. Classification of Medical Devices Circular 57 classifies medical devices into six groups (from Group 1 to Group 6) based on technical standards and quality. Medical devices subject to classification must simultaneously meet technical standards and quality requirements in accordance with professional specifications and user needs, and must be lawfully marketed in Vietnam. Medical devices manufactured in Vietnam may participate in all corresponding groups, provided they meet the technical standards required by the user and are lawfully marketed in Vietnam. Outlook Circular No. 57 will take effect on February 15, 2026, while the classification requirements will become effective on January 1, 2027. Holders of medical
Read More
December 30, 2025
The Intellectual Property Office of Vietnam (IP Office), with support from the Japan International Cooperation Agency (JICA), is drafting additional annexes to its Guidelines for Patent Examination, focusing on the examination of patent applications in the pharmaceutical and biotechnology sectors. The new annexes are expected to be officially issued in early 2026 as Annexes III and IV, following the successful issuance in 2023 of Annexes I and II addressing computer program-related inventions. The IP Office recently organized a seminar to gather feedback on the draft annexes from intellectual property representatives, academic institutions, research institutes, and other interested parties, emphasizing its intention to receive further constructive opinions to refine the guidelines for pharmaceuticals and biotechnology. Why These Guidelines Matter Patent examination in Vietnam has traditionally relied on the Guidelines for Patent Examination issued under Decision No. 487/QD-SHTT (2010), recently supplemented by Annexes I and II. While these documents provide a solid foundation, they do not fully address practical challenges in examining pharmaceutical and biotech inventions, particularly issues related to clarity, sufficiency of disclosure, enablement, features of function and utility, combination therapies, and inventions involving artificial intelligence (AI) applications in these fields. Annexes III and IV aim to close these gaps by introducing structured principles and illustrative examples. Guidance on Patent Specification Requirements Annex III provides detailed guidance on the requirements for patent specifications in pharmaceuticals and biotechnology, covering two main parts: Part A addresses sufficiency of disclosure, clarity of specifications, and consistency between claims and descriptions. Part B covers inventions related to Markush-type compounds, claims containing exclusion statements (disclaimers), and additional experimental data submitted during examination. The Guidelines outline specific disclosure requirements for subject matters such as compounds, formulations, pharmaceutical compositions, genes, polypeptides, proteins, vectors, transgenic organisms, modified organisms, and hybrid cells. Annex III emphasizes that disclaimers are not accepted
Read More